Skip to main content

Clinical Trials

Treatment of Patients With Node-Positive, HR-Positive/HER2-Negative Early Breast Cancer at High Risk of Recurrence: monarchE 7-Year Outcomes

Pharmacist-Led Management of Concomitant Medications in Oncology Trials: A Retrospective Analysis of Screening and Enrollment Outcomes

A. Cameron Hill, PharmD, PhD; Camryn Froerer, PharmD, MS, BCSCP, BCPS; Benjamin Maughan, MD, PharmD

Review of the Regulatory Framework for Interstate Shipping of Investigational New Drugs

Donaciano Dominguez, PharmD, MBA; Jennifer Murphy, PharmD, BCOP; Matthew Serna, PharmD, BCPS; Tala Ataya, PharmD, MBA

Quality Improvement Strategies to Optimize Outpatient Step-Up Dosing for Elranatamab in Relapsed/Refractory Multiple Myeloma

North American Enrollment in Clinical Trials: An Emerging Issue for Regulatory Approval

Ming-Hei Tai, PharmD, BCOP

Pirtobrutinib in Covalent BTKi-Treated Patients With CLL/SLL: Translating Clinical Trial Insights Into Real-World Practice

AUGTYRO (Repotrectinib) for the Treatment of ROS1-Positive Non-Small Cell Lung Cancer

The Evolution of Abemaciclib Clinical Trial Data for the Treatment of HR-Positive/HER2-Negative Metastatic Breast Cancer

Identification and Treatment of Patients With Hormone Receptor–Positive, HER2-Negative Early Breast Cancer at High Risk of Recurrence: monarchE Study Long-Term Outcomes

Pirtobrutinib in Pretreated Patients With CLL/SLL: Applying Lessons From Clinical Trials to Clinical Practice

Page 1 of 3
Results 1 - 10 of 21